**Supplementary Table 1: The quality rating of the included studies using the NIH Quality Assessment Tool for Case Series Studies**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Questions** | | | | | | | | | **Overall Rating** | |
| **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** | **Reviewer 1** | **Reviewer 2** |
| Puntmann et al 21 | Yes | Yes | NR | Yes | NA | Yes | NA | Yes | Yes | Fair | Fair |
| Knight et al 11 | Yes | Yes | NR | CD | NA | Yes | NR | NR | Yes | Fair | Fair |
| Blondiaux et al 10 | Yes | Yes | NR | CD | NA | Yes | Yes | NR | Yes | Fair | Fair |
| Esposito et al 30 | Yes | Yes | NR | CD | NA | Yes | Yes | NR | Yes | Fair | Fair |
| Huang et al 25 | Yes | Yes | Yes | Yes | NA | Yes | NR | Yes | Yes | Fair | Fair |
| Lam et al 31 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Coyle et al 32 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Besler et al 33 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Inciardi et al 18 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Gravinay et al 12 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Trogen et al 34 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Luetkens et al 35 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Manka et al 36 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Pavon et al 37 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Sardari et al 38 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Gnecchi et al 39 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Paul et al 40 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Sala et al 20 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Bonnet et al 13 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Kim et al 27 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Doyen et al 41 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Warchol et al 17 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Sassone et al 42 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Salamanca et al 43 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Nicola et al 14 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Fischer et al 19 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Torres et al 44 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Weinsaft et al 45 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Madamanchi et al 46 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Yuan et al 22 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Garot et al 23 | Yes | Yes | NA | NA | NA | Yes | Yes | NA | Yes | Fair | Fair |
| Monmeneu et al 15 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Oberweis et al 16 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |
| Legrand et al 47 | Yes | Yes | NA | NA | NA | Yes | CD | NA | Yes | Fair | Fair |

NIH = National Institutes of Health, CD, cannot determine; NA, not applicable; NR, not reported

\*The list of 9 questions from the NIH Quality Assessment Tool for Case Series Studies:

1. Was the study question or objective clearly stated?
2. Was the study population clearly and fully described, including a case definition?
3. Were the cases consecutive?
4. Were the subjects comparable?
5. Was the intervention clearly described?
6. Were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants?
7. Was the length of follow-up adequate?
8. Were the statistical methods well-described?
9. Were the results well-described?

(Source: National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH))